Abbott Laboratories Company Profile (NYSE:ABT)

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories logoAbbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:ABT
  • CUSIP: 00282410
  • Web:
  • Market Cap: $85.77449 billion
  • Outstanding Shares: 1,735,272,000
Average Prices:
  • 50 Day Moving Avg: $48.18
  • 200 Day Moving Avg: $44.68
  • 52 Week Range: $37.38 - $51.13
  • Trailing P/E Ratio: 52.91
  • Foreward P/E Ratio: 18.36
  • P/E Growth: 1.81
Sales & Book Value:
  • Annual Revenue: $22.3 billion
  • Price / Sales: 3.96
  • Book Value: $18.07 per share
  • Price / Book: 2.81
  • Annual Dividend: $1.06
  • Dividend Yield: 2.1%
  • EBIDTA: $4.77 billion
  • Net Margins: 6.74%
  • Return on Equity: 14.91%
  • Return on Assets: 6.91%
  • Debt-to-Equity Ratio: 0.75%
  • Current Ratio: 2.91%
  • Quick Ratio: 2.31%
  • Average Volume: 6.25 million shs.
  • Beta: 1.07
  • Short Ratio: 2.82

Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories announced a quarterly dividend on Friday, June 9th. Stockholders of record on Friday, July 14th will be given a dividend of $0.265 per share on Tuesday, August 15th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 2.08%. The ex-dividend date of this dividend is Wednesday, July 12th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) posted its earnings results on Thursday, July, 20th. The company reported $0.62 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.60 by $0.02. The company earned $6.64 billion during the quarter, compared to analyst estimates of $6.63 billion. Abbott Laboratories had a return on equity of 14.91% and a net margin of 6.74%. The firm's revenue was up 24.5% on a year-over-year basis. During the same quarter last year, the company earned $0.55 EPS. View Abbott Laboratories' Earnings History.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its third quarter earnings guidance on Thursday, July, 20th. The company provided EPS guidance of $0.64-0.66 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.66. Abbott Laboratories also updated its FY17 guidance to $2.43-2.53 EPS.

Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?

14 analysts have issued 1 year target prices for Abbott Laboratories' shares. Their predictions range from $42.00 to $58.00. On average, they anticipate Abbott Laboratories' stock price to reach $51.85 in the next year. View Analyst Ratings for Abbott Laboratories.

What are analysts saying about Abbott Laboratories stock?

Here are some recent quotes from research analysts about Abbott Laboratories stock:

  • 1. According to Zacks Investment Research, "For the majority of last one month, Abbott is trading above the broader Medical Products industry. We are optimistic about the company’s strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Recently, Abbott received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. The company also launched science-based nutrition drinks for better recovery from surgeries. On the flip side, Abbott’s sluggish pediatric business in China continues to hamper growth. Management is also concerned about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters." (6/21/2017)
  • 2. Jefferies Group LLC analysts commented, "Investment summary: We are reiterating our Overweight rating for CORI and we are raising our PT by $2 to $12 following the positive donepezil patch bioequivalence results. Progress in the development of a proprietary pipeline is key, in our opinion, to the performance of the shares. Successful development of patch formulations of donepezil (Aricept) and/or memantine (Namenda) should position the company well to more-effectively monetize the transdermal drug delivery platform, in our opinion. Retention of meaningful commercialization rights could enable the company to turn the corner and pursue other opportunities more broadly, in our opinion. Corplex donepezil pilot study shows bioequivalence. Management reported that the Corplex donepezil pilot study met the FDA statistical criteria for bioequivalence. We note, too, that the patch was well-tolerated, with good skin and GI tolerability." (5/12/2017)

Who are some of Abbott Laboratories' key competitors?

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:

  • Miles D. White, Chairman of the Board, Chief Executive Officer
  • Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance
  • Michael T. Rousseau, President - Cardiovascular and Neuromodulation
  • Hubert L. Allen, Executive Vice President, General Counsel, Secretary
  • Stephen R. Fussell, Executive Vice President - Human Resources
  • Brian J. Blaser, Executive Vice President - Diagnostics Products
  • John M. Capek Ph.D., Executive Vice President - Ventures
  • Robert B. Ford, Executive Vice President - Medical Devices
  • Heather L. Mason, Executive Vice President - Nutritional Products
  • Roger Bird, Senior Vice President - U.S. Nutrition

Who owns Abbott Laboratories stock?

Abbott Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vontobel Asset Management Inc. (0.22%), US Bancorp DE (0.19%), Rockefeller Financial Services Inc. (0.15%), Jarislowsky Fraser Ltd (0.14%), NN Investment Partners Holdings N.V. (0.12%) and APG Asset Management N.V. (0.12%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including DnB Asset Management AS, APG Asset Management N.V., Bank of Montreal Can, Vontobel Asset Management Inc., NN Investment Partners Holdings N.V., Rockefeller Financial Services Inc., Exxonmobil Investment Management Inc. TX and Meeder Asset Management Inc.. Company insiders that have sold Abbott Laboratories stock in the last year include Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?

Abbott Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including Hexavest Inc., Fisher Asset Management LLC, Mn Services Vermogensbeheer B.V., National Pension Service, Pennsylvania Trust Co, Aperio Group LLC, Sit Investment Associates Inc. and Jarislowsky Fraser Ltd. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

How do I buy Abbott Laboratories stock?

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of Abbott Laboratories stock can currently be purchased for approximately $50.85.

MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  514 (Vote Outperform)
Underperform Votes:  368 (Vote Underperform)
Total Votes:  882
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Abbott Laboratories (NYSE:ABT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.79)
Consensus Price Target: $51.85 (1.96% upside)

Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017Cowen and CompanyReiterated RatingOutperform$48.00 -> $55.00LowView Rating Details
7/11/2017BMO Capital MarketsReiterated RatingHold$48.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual WeightLowView Rating Details
6/30/2017Wells Fargo & CompanyReiterated RatingOutperform$47.50 -> $54.00LowView Rating Details
6/29/2017Jefferies Group LLCReiterated RatingBuy$58.00LowView Rating Details
6/29/2017GuggenheimInitiated CoverageBuy$58.00LowView Rating Details
6/21/2017BTIG ResearchInitiated CoverageBuy$56.00LowView Rating Details
5/31/2017Stifel NicolausBoost Price TargetBuy$49.00 -> $51.00MediumView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral -> Neutral$45.00LowView Rating Details
5/15/2017Royal Bank Of CanadaReiterated RatingBuyLowView Rating Details
4/20/2017Barclays PLCBoost Price TargetOverweight -> Overweight$50.00 -> $52.00LowView Rating Details
9/19/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
8/9/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
7/28/2016ArgusReiterated RatingBuy$55.00N/AView Rating Details
6/21/2016Edward JonesUpgradeHold -> BuyN/AView Rating Details
6/8/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
4/30/2016S&P Equity ResearchReiterated RatingHoldN/AView Rating Details
4/30/2016GabelliReiterated RatingBuyN/AView Rating Details
4/28/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
4/14/2016First GlobalDowngradeOutperform -> MarketperformN/AView Rating Details
3/28/2016Leerink SwannBoost Price TargetMarket Perform$37.00 -> $40.00N/AView Rating Details
1/29/2016Raymond James Financial, Inc.Lower Price TargetOutperform$46.00 -> $42.00N/AView Rating Details
1/29/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 7/21/2015 forward)


Earnings History for Abbott Laboratories (NYSE:ABT)
Earnings by Quarter for Abbott Laboratories (NYSE:ABT)
Earnings History by Quarter for Abbott Laboratories (NYSE ABT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/20/2017Q2 2017$0.60$0.62$6.63 billion$6.64 billionViewN/AView Earnings Details
4/19/20173/31/2017$0.43$0.48$6.16 billion$6.34 billionViewN/AView Earnings Details
1/25/2017Q416$0.64$0.65$5.41 billion$5.33 billionViewListenView Earnings Details
10/19/2016Q316$0.58$0.59$5.29 billion$5.30 billionViewListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.68$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.60$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Abbott Laboratories (NYSE:ABT)
2017 EPS Consensus Estimate: $2.43
2018 EPS Consensus Estimate: $2.85
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.43$0.50$0.45
Q2 20173$0.59$0.61$0.60
Q3 20173$0.64$0.68$0.65
Q4 20173$0.72$0.73$0.73
Q1 20181$0.56$0.56$0.56
Q2 20181$0.71$0.71$0.71
Q3 20181$0.74$0.74$0.74
Q4 20181$0.84$0.84$0.84
(Data provided by Zacks Investment Research)


Current Dividend Information for Abbott Laboratories (NYSE:ABT)
Next Dividend:8/15/2017
Annual Dividend:$1.06
Dividend Yield:2.08%
Dividend Growth:22.90% (3 Year Average)
Payout Ratio:110.42% (Trailing 12 Months of Earnings)
42.91% (Based on This Year's Estimates)
38.27% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Dividend History by Quarter for Abbott Laboratories (NYSE ABT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)
Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 71.02%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/15/2017Jared WatkinInsiderSell552$47.97$26,479.44View SEC Filing  
6/8/2017Stephen R FussellInsiderSell196,550$46.00$9,041,300.00View SEC Filing  
4/27/2017Roger BirdInsiderSell5,600$43.82$245,392.00View SEC Filing  
4/26/2017Joseph J ManningInsiderSell4,200$43.95$184,590.00View SEC Filing  
3/1/2017Michael J. WarmuthInsiderSell3,851$45.39$174,796.89View SEC Filing  
2/23/2017Robert E FunckVPSell25,500$45.50$1,160,250.00View SEC Filing  
2/22/2017Roger BirdInsiderSell13,222$45.02$595,254.44View SEC Filing  
2/21/2017Deepak S NathInsiderSell319$44.98$14,348.62View SEC Filing  
1/31/2017Heather L MasonInsiderSell35,700$40.77$1,455,489.00View SEC Filing  
12/20/2016Brian J BlaserInsiderBuy15,580$38.45$599,051.00View SEC Filing  
12/14/2016Robert B FordInsiderBuy12,775$39.09$499,374.75View SEC Filing  
11/10/2016Miles D WhiteChairmanBuy121,456$40.45$4,912,895.20View SEC Filing  
11/1/2016Sally E BlountDirectorBuy5,100$39.24$200,124.00View SEC Filing  
9/26/2016Daniel Gesua Sive SalvadoriSVPSell815$41.71$33,993.65View SEC Filing  
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.00View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.46View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.00View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.76View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.85View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.43View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.36View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.80View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.11View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.68View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.90View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.86View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.23View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.00View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.34View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.39View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.61View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.30View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.30View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Abbott Laboratories (NYSE:ABT)
Latest Headlines for Abbott Laboratories (NYSE:ABT)
DateHeadline logoZacks: Brokerages Anticipate Abbott Laboratories (NYSE:ABT) to Announce $0.66 EPS - July 21 at 9:54 AM logoAbbott Q2 Profit Falls, But Results Top View; Lifts 2017 Profit Outlook - July 21 at 1:34 AM logoLabCorp (LH) Q2 Earnings: Is Disappointment in the Cards? - July 20 at 8:30 PM logoAbbott Laboratories (ABT) Releases Q3 Earnings Guidance - July 20 at 5:38 PM logoAbbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up - Nasdaq - July 20 at 3:28 PM logoAbbott (ABT) Tops Earnings Estimates in Q2, Misses on Sales - July 20 at 3:28 PM logoUS STOCKS-Wall St flat as earnings from some big names disappoint - July 20 at 3:28 PM logoAbbott Zeros In On A 2-Year High After Topping Q2 Sales, Profits - July 20 at 3:28 PM logoUS STOCKS-Wall St flat as consumer stocks, weak earnings weigh - July 20 at 3:28 PM logoAbbott CEO: Another Alere-Related Divestiture Coming Soon - July 20 at 3:28 PM logoAbbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up - July 20 at 3:28 PM logoAbbott profit forecast gets a lift from St. Jude integration - July 20 at 3:28 PM logoAbbott tops Street 2Q forecasts - July 20 at 3:28 PM logoUS STOCKS-S&P, Dow flat as retailers weigh; Nasdaq edges higher - July 20 at 3:28 PM logoAbbott Laboratories (ABT) Releases Earnings Results - July 20 at 9:53 AM logoAbbott Laboratories (ABT) Releases FY17 Earnings Guidance - July 20 at 9:42 AM logoWhat To Watch For In Abbott's Q2 Earnings - Nasdaq - July 19 at 3:36 PM logoMedical Product Stocks' Earnings on Jul 20: ABT, ISRG & More - Nasdaq - July 19 at 3:36 PM logoAbbott Laboratories (NYSE:ABT), American Express Company ... - Benzinga - July 19 at 3:36 PM logoQuidel Diversifies With Alere's Triage Assets - - July 18 at 8:39 PM logoQuidel Diversifies With Alere's Triage Assets - July 18 at 8:39 PM logoRisk Arbitrage Today: 2 M&A Deals That Had Price Cuts With A Little Meat Left On The Bone - July 18 at 3:36 PM logoAbbott's Tarnished Deal Sparkles for Another - July 18 at 3:35 PM logoCan Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings? - Nasdaq - July 18 at 1:43 AM logoCan Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings? - July 17 at 8:40 PM logoEarnings Roundup: JNJ, IBM, And LMT Report Q2 Results Tomorrow - Benzinga - July 17 at 3:37 PM logoScience: Sugar substitute effects not so sweet - July 17 at 3:37 PM logoCorporate America Is About to Unleash Great Earnings Reports, Hopefully: Week Ahead - - July 16 at 8:32 AM logoAbbott Labs (ABT) PT Raised to $55 at Cowen; 'Refining Sales ... - - July 14 at 10:15 PM logoABT: Wall Street Analysts’ Recommendations ahead of Q2 Earnings - July 14 at 5:10 PM logoWill Abbott Laboratories Beat Analyst Revenue Estimates in Q2? - July 14 at 5:10 PM logoWhat to Expect from Abbott Laboratories’ 2Q17 Earnings - July 14 at 5:10 PM logoCowen and Company Reiterates "Outperform" Rating for Abbott Laboratories (ABT) - July 14 at 1:25 PM logoTraders Buy Large Volume of Abbott Laboratories Call Options (NYSE:ABT) - July 14 at 7:34 AM logoAbbott teams up with Bigfoot Bio in diabetes management - Seeking Alpha - July 14 at 1:52 AM logoAbbott, Novartis Show Promise Amid Healthcare Decline, Tiffany Lands Much Needed Boost -ICYMI Thurs. - - July 14 at 1:52 AM logoAbbott Laboratories (ABT) Set to Announce Quarterly Earnings on Thursday - July 13 at 9:20 PM logoAbbott and Bigfoot Biomedical Announce Collaboration to Develop Breakthrough Diabetes Technologies - July 13 at 3:45 PM logoAbbott Laboratories Is Set for Another Breakout - July 13 at 3:45 PM logoMajor Transformations For Abbott Are Paying Off - July 12 at 8:49 PM logoEdwards Emerges Strong on FDA Nods, International Prospect - Nasdaq - July 12 at 3:46 PM logoLabCorp Diagnostics Strong on Novant Health Deal Extension - July 12 at 3:46 PM logoEdwards Emerges Strong on FDA Nods, International Prospect - July 12 at 3:46 PM logoAbbott Laboratories (ABT) Ex-Dividend Date Scheduled for July 12, 2017 - Nasdaq - July 11 at 9:26 PM logoThe Number One Defensive Blue-Chip To Buy Today? - July 11 at 4:24 PM logoFeatured Company News - Alere Announces Approval of Amended Merger Agreement by Shareholders with Abbott Labs - July 11 at 4:24 PM logoMorgan Stanley Reiterates Equal Weight Rating for Abbott Laboratories (NYSE:ABT) - July 10 at 11:32 PM logoInvestors Look for Gains as Abbott Labs Set to Acquire Alere - July 10 at 3:25 PM logoThermo Fisher at a 52-Week High: What's Driving the Stock? - July 10 at 3:25 PM logoA Look at Abbott Laboratories Stock for 2Q17 - July 10 at 3:25 PM



Abbott Laboratories (ABT) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by Staff